---
title: "Key facts: BTAI plans at-home IGALMI launch; Q4 adjusted loss $0.58"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286637666.md"
description: "BTAI readies at-home launch for IGALMI, citing market assessment-driven plan, investor briefings, brand awareness efforts and limited commercial resources.1BioXcel Therapeutics (BTAI) Q4 adjusted loss $0.58 vs $3.57 year-ago; revenue fell 43.7% to $206K; net loss $12.55M. Shares down 9.7% for quarter, 24.4% YTD; median 12‑month target $8.00.2"
datetime: "2026-05-16T07:14:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286637666.md)
  - [en](https://longbridge.com/en/news/286637666.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286637666.md)
---

# Key facts: BTAI plans at-home IGALMI launch; Q4 adjusted loss $0.58

-   BTAI readies at-home launch for IGALMI, citing market assessment-driven plan, investor briefings, brand awareness efforts and limited commercial resources.1
-   BioXcel Therapeutics (BTAI) Q4 adjusted loss $0.58 vs $3.57 year-ago; revenue fell 43.7% to $206K; net loss $12.55M. Shares down 9.7% for quarter, 24.4% YTD; median 12‑month target $8.00.2

### Related Stocks

- [BTAI.US](https://longbridge.com/en/quote/BTAI.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)